SCHEMBL23478409

SCHEMBL23478409

N#Cc1ccc2ncc(Cl)n2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
FLT3 P36888 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.41
IRAK1 P51617 1/20 0.41
JAK2 O60674 2/20 0.35
JAK3 P52333 2/20 0.35
JAK1 P23458 1/20 0.35
AHR P35869 2/20 0.35
MKNK1 Q9BUB5 2/20 0.35
MKNK2 Q9HBH9 2/20 0.35
CYP3A4 P08684 1/20 0.35
EIF4E P06730 1/20 0.35
TGFBR1 P36897 1/20 0.35
EGLN2 Q96KS0 2/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CG P48736 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178803 0.79 ALDH1A1 (0.45) PRMT5WDR77FLT3IRAK4IRAK1
SCHEMBL22095679 0.79 FLT3 (0.41) PRMT5WDR77FLT3IRAK4IRAK1
SCHEMBL17102325 0.79 FLT3 (0.41) PRMT5WDR77FLT3IRAK4IRAK1
SCHEMBL2177773 0.75 CYP11B2 (0.42) PRMT5WDR77FLT3IRAK4IRAK1
SCHEMBL21194708 0.74 EIF2AK4 (0.48) PRMT5WDR77FLT3IRAK4IRAK1
SCHEMBL3313303 0.74 IGF1R (0.46) PRMT5WDR77FLT3IRAK4IRAK1
SCHEMBL9941943 0.73 TGFBR1 (0.44) PRMT5WDR77FLT3IRAK4IRAK1
SCHEMBL31423373 0.73 POLB (0.41) MKNK1MKNK2TGFBR1PIK3CDPIK3CG
SCHEMBL2049652 0.72 TGFBR1 (0.43) PRMT5WDR77FLT3IRAK4IRAK1
SCHEMBL22125606 0.72 MAP3K14 (0.50) FLT3AHRPIK3CGALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 US disclosed
WO-2021113682-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 WO disclosed
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 PRMT5 810/4885WDR77 1013/4885FLT3 3948/4885
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 PRMT5 810/4885WDR77 1013/4885FLT3 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.